将个体早期反应纳入直肠癌新辅助放化疗后病理完全缓解的剂量-效应关系模型
本研究开发并外部验证了一个结合经典logit剂量-效应曲线与放疗期间磁共振成像评估的个体早期反应(ERI)的模型,用于预测直肠癌新辅助放化疗后的病理完全缓解(pCR)。模型在95例推导队列中拟合,并在132例外部队列中验证,显示出良好的校准和区分能力,且按ERI分层的剂量-pCR关系支持其预测价值。
要点
- ERI基于的Hill模型在外部验证中表现出稳健的区分能力(AUC 0.77,平均精度0.65)。
- 按ERI分层,高反应组pCR达65%,中反应组55%,低反应组14%和35%,无反应组0%。
- 在中至好反应者中,等效均匀剂量2 Gy增加8.5 Gy约对应pCR提高20%,而无反应者无获益。
核心结论
- ERI-剂量模型在具有不同放疗方案的外部队列中得到验证,支持基于ERI优化剂量提升以个性化放疗方案。
研究设计与样本
- 研究为模型开发与外部验证,推导队列为San Raffaele医院95例患者,外部队列为Policlinico Gemelli医院132例患者。
- 模型将ERI作为动态剂量修饰因子纳入基于等效均匀剂量2 Gy并包含时间因子的Hill模型。
- 使用校准图、曲线下面积和平均精度评估模型性能,并对externa队列进行重校准。
主要发现
- 最终Hill模型最佳拟合值为TD50=52.2 Gy,动态剂量修饰因子=(0.89+0.02×ERI),陡度k=5.91+0.11×ERI。
- 验证队列pCR率为35.6%,预测与观察率高度一致(偏移0,斜率0.84)。
- 区分能力稳健:曲线下面积0.77,平均精度0.65(基线0.356)。
- 按ERI分层:高反应(ERI 1-6.9)pCR 65%,中反应(ERI 6.9-13.1)pCR 55%,低反应(ERI 13.1-36)pCR 14%和35%,无反应(ERI>36)pCR 0%。
关键数值与推荐
- ERI分层标准:高反应1-6.9,中反应6.9-13.1,低反应13.1-36,无反应>36。
- 在中至好反应者中,等效均匀剂量2 Gy增加8.5 Gy对应pCR提高约20%,无反应者无获益。
临床怎么用
- 可利用放疗期间MRI评估的ERI对直肠癌患者进行早期反应分层,指导个体化剂量提升决策。
- 对于中至好反应者,考虑剂量提升8.5 Gy(等效均匀剂量2 Gy)以增加pCR概率;无反应者可能避免不必要的剂量提升。
局限性
- 原文未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop and externally validate a model predicting pathological complete response (pCR) in patients with rectal cancer treated with neoadjuvant radiochemotherapy. The approach combines the classical logit dose-effect curve with individual early response assessed by magnetic resonance imaging during radiochemotherapy. METHODS AND MATERIALS: The dose-response model incorporating the early regression index (ERI) was derived from 2 published data sets. A population-averaged dose-response curve was obtained by fitting data from a recent meta-analysis. Then, an ERI-based model for pCR prediction was fit to 95 patients treated at San Raffaele Hospital; ERI was incorporated as a dynamic dose-modifying factor in the Hill model, based on Equivalent Uniform Dose to 2 Gy and including the time factor. The model was validated on an external cohort of 132 patients treated at Policlinico Gemelli with standard and dose-escalated schedules. Calibration plots, area under the curve, and average precision were used to assess performance. Recalibration refined predictions for the external cohort. RESULTS: The final Hill model showed best-fit values of TD50 = 52.2 Gy, dynamic dose-modifying factor = (0.89 + 0.02 × ERI), and steepness k = 5.91 + 0.11 × ERI. The validation cohort had a pCR rate of 35.6%. Agreement between prediction and observed rates was high (offset, 0; slope, 0.84). Discriminative ability was robust (area under the curve, 0.77; average precision, 0.65 vs 0.356 for baseline). ERI-stratified dose-pCR relationships confirmed predictive value across 4 ERI categories: highly responsive (ERI, 1-6.9; pCR, 65%), moderately responsive (ERI, 6.9-13.1; pCR, 55%), poorly responsive (ERI, 13.1-36; pCR, 14% and 35%), and nonresponsive (ERI, >36; pCR, 0%). Predictions aligned with results using median ERI values per group. CONCLUSIONS: The ERI-dose model was validated on an external cohort with distinct radiation therapy regimens. Dose escalation of 8.5 Equivalent Uniform Dose to 2 Gy in moderate-to-good responders corresponds to an increase of approximately 20% in pCR, whereas no benefit was reported in nonresponders. These findings highlight the model's potential for personalizing radiation therapy protocols by optimizing dose escalation based on ERI.
引用
- Cicchetti A, Mori M, Passoni P, et al. Incorporating Individual Early Response in the Dose-Effect Relationship of Complete Pathological Response Following Neoadjuvant Radiochemotherapy for Rectal Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 41354181. doi:10.1016/j.ijrobp.2025.11.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。